Basic Information
Afstyla
Regulatory Information
EMEA/H/C/004075
Authorised
January 4, 2017
November 10, 2016
11
December 18, 2024
Company Information
Germany
Emil-von-Behring Strasse 76 35041 Marburg
Csl Behring Gmbh
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Afstyla can be used for all age groups.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Afstyla. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Afstyla. For practical information about using Afstyla, patients should read the package leaflet or contact their doctor or pharmacist.